Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals, Inc. (AMLX)
:AMLX
RESEARCH TOOLSreports
Top Page
Amylyx Pharmaceuticals Inc
(NASDAQ:AMLX)
55Neutral
Positive Factors
Drug Efficacy
Avexitide, a GLP-1 receptor antagonist acquired by Amylyx, has shown promising Phase 2 results with a significant reduction in hypoglycemia events.
Financial Stability
Amylyx has sufficient cash into 2026 despite a net loss in 3Q25, providing a financial cushion for ongoing developments.
Negative Factors
Pipeline Risk
The rest of Amylyx's pipeline beyond avexitide is viewed as having a relatively low probability of approval and is considered as upside for valuation.
Amylyx Pharmaceuticals Inc (AMLX) vs. S&P 500 (SPY)
Market Cap
$309.22M
Dividend YieldN/A
Average Volume (3M)819.27K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth-77.06%
EPS Growth-705.82%
CountryUS
Employees384
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.43
Shares Outstanding88,602,470
10 Day Avg. Volume954,363
30 Day Avg. Volume819,271
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.54
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.67Price Target Upside148.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Amylyx Pharmaceuticals Inc Business Overview & Revenue Model
Company DescriptionAmylyx Pharmaceuticals Inc (AMLX) is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company operates primarily in the healthcare and pharmaceuticals sector, striving to address unmet medical needs through the development of novel treatment options. Its core product includes AMX0035, a proprietary combination of sodium phenylbutyrate and taurursodiol, aimed at treating conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders.
How the Company Makes MoneyAmylyx Pharmaceuticals Inc generates revenue primarily through the sale of its approved drug, AMX0035, marketed under the brand name Relyvrio in the United States and Albrioza in Canada. The company profits from sales to healthcare providers and institutions treating patients with neurodegenerative diseases. Additionally, revenue streams may include partnerships or collaborations with other pharmaceutical companies or research institutions involved in drug development and commercialization. Regulatory approvals and successful market penetration significantly contribute to the company's earnings, as they allow Amylyx to expand its market reach and increase sales volume.
Amylyx Pharmaceuticals Inc Financial Statement Overview
Summary
Amylyx Pharmaceuticals faces significant financial challenges, with declining revenues and substantial operational losses reflected in negative profit margins. The balance sheet shows a relatively low level of debt and strong equity ratio, although historical negative equity points to potential financial instability. Cash flow analysis reveals persistent cash generation issues, which could impact future operational sustainability. The company needs to address its declining revenue and improve operational efficiency to enhance financial health.Income Statement
The company's revenue showed a significant decrease from 2023 to 2024, indicating a revenue growth rate of -77.05%. Despite having a gross profit margin of 51.76% in 2024, the net profit margin was highly negative at -345.20%, reflecting substantial operational losses. The EBIT and EBITDA margins were also negative, highlighting ongoing profitability challenges.40
Negative
Balance Sheet
Amylyx Pharmaceuticals maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt. However, the company has a strong equity ratio of 85.10%, indicating that a majority of the assets are financed by shareholders' equity. Despite this, the company has consistently reported negative equity in previous years, pointing to financial instability risks.55
Neutral
Cash Flow
The company experienced a decline in free cash flow from 2023 to 2024, with a negative growth rate of -1671.46%. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. This indicates ongoing cash flow challenges, as the company is not generating sufficient cash from operations to cover its expenses.35
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 87.37M | 380.79M | 22.23M | 285.00K | 650.00K | Gross Profit |
| 45.22M | 355.35M | 19.24M | 233.00K | -23.94M | EBIT |
| -314.73M | 38.80M | -201.34M | -82.69M | -39.01M | EBITDA |
| -290.98M | 39.89M | -200.85M | -82.64M | -39.00M | Net Income Common Stockholders |
| -301.74M | 49.27M | -198.38M | -87.88M | -44.84M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 176.50M | 371.36M | 346.94M | 96.12M | 12.88M | Total Assets |
| 193.63M | 517.45M | 391.45M | 105.61M | 14.10M | Total Debt |
| 1.98M | 4.24M | 6.28M | 0.00 | 1.43M | Net Debt |
| -75.41M | -165.96M | -56.25M | -50.19M | -11.45M | Total Liabilities |
| 28.87M | 84.02M | 50.85M | 256.78M | 80.83M | Stockholders Equity |
| 164.76M | 433.43M | 340.61M | -151.17M | -66.72M |
| Cash Flow | Free Cash Flow | |||
| -167.80M | 10.68M | -182.40M | -75.15M | -36.85M | Operating Cash Flow |
| -167.65M | 11.92M | -179.87M | -74.80M | -36.70M | Investing Cash Flow |
| 75.65M | 92.05M | -238.99M | -46.41M | -151.00K | Financing Cash Flow |
| 348.00K | 3.54M | 431.79M | 158.51M | 46.82M |
Amylyx Pharmaceuticals Inc Technical Analysis
Positive
3.49
Price Trends
3.54
Positive
4.30
Negative
3.26
Positive
Market Momentum
-0.01
Negative
55.47
Neutral
72.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 3.49 is above the 20-day moving average (MA) of 3.40, below the 50-day MA of 3.54, and above the 200-day MA of 3.26, indicating a bullish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.47 is Neutral, neither overbought nor oversold. The STOCH value of 72.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.
Amylyx Pharmaceuticals Inc Risk Analysis
Amylyx Pharmaceuticals Inc disclosed 90 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amylyx Pharmaceuticals Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $21.03B | 12.85 | 10.36% | ― | -1.60% | 39.71% | |
56 Neutral | $4.14B | ― | 33.08% | ― | -13.97% | 43.51% | |
55 Neutral | $309.22M | ― | -100.88% | ― | -77.06% | -705.82% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
48 Neutral | $763.88M | ― | -37.72% | ― | ― | -3.08% | |
45 Neutral | $5.13B | ― | 435.49% | ― | 145.34% | 3.20% | |
43 Neutral | $4.07B | ― | -76.34% | ― | 95.41% | -97.85% |
* Healthcare Sector Average
Performance Comparison
AMLX
Amylyx Pharmaceuticals Inc
3.73
0.29
8.43%
BIIB
Biogen
143.66
-83.70
-36.81%
CYTK
Cytokinetics
44.40
-20.15
-31.22%
PTCT
PTC Therapeutics
52.59
20.90
65.95%
AVXL
Anavex Life Sciences
8.98
3.78
72.69%
IONQ
IonQ
18.70
8.83
89.46%
Amylyx Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date: Mar 4, 2025 | % Change Since: 16.33% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook with significant advancements in clinical trials and a strong financial position. However, there are challenges related to operational cash use and the inherent risks in clinical and regulatory processes.Highlights
Strong Financial Position
Amylyx ended 2024 with a solid cash position of $176.5 million, not including $65.5 million from a recent public offering, securing a runway through 2026.
Avexitide Advancements
Phase III LUCIDITY trial for avexitide in PBH is underway, with significant reductions in hypoglycemic events in previous trials (53% reduction in Level 2 and 66% in Level 3 events).
Pipeline Progress
Key milestones expected within 12-15 months across multiple programs: avexitide, AMX0035, and AMX0114.
Successful Financing
Raised approximately $65.5 million to support commercial preparations for avexitide and extend cash runway.
Lowlights
Operational Cash Use
Used $27 million in cash for ongoing operations and an additional $31 million for previously recognized obligations related to product discontinuation.
Regulatory and Clinical Risks
Ongoing reliance on future clinical trial success and regulatory approvals for pipeline products, presenting potential risks.
Company Guidance
During the Amylyx Pharmaceuticals' Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided guidance on several key metrics and upcoming milestones. The company raised approximately $65.5 million to support commercial preparations for avexitide, aiming to extend its cash runway through 2026. They are conducting four ongoing clinical trials, focusing on orphan diseases. The pivotal Phase III LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH) began recruiting in February 2025, with top-line data expected in the first half of 2026. Avexitide has a 53% reduction in Level 2 and a 66% reduction in Level 3 hypoglycemic events. AMX0035 is being evaluated for Wolfram syndrome and progressive supranuclear palsy (PSP) with Phase II and III trials expected to show significant results. The financial outlook shows operating expenses for Q4 2024 were $39.9 million, a 62% decrease from the previous year, with a solid cash position of $176.5 million at the end of 2024, excluding new financing. The company anticipates commercial launch in 2027, assuming positive outcomes from ongoing trials.Amylyx Pharmaceuticals Inc Corporate Events
Business Operations and Strategy
Amylyx Partners with Gubra for GLP-1 Antagonist
Positive
Dec 30, 2024
Amylyx Pharmaceuticals Inc. has entered into a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist. This partnership involves Amylyx making upfront and research payments and Gubra potentially receiving over $50 million in milestones and royalties, with the collaboration expected to enhance Amylyx’s cash runway into 2026.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.